The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents
Sean T. O’Leary(University of Colorado Anschutz Medical Campus), Robert Ball(Center for Drug Evaluation and Research), David L. McClure(Marshfield Clinic), Cynthia Nakasato(Kaiser Permanente), Héctor S. Izurieta(Center for Biologics Evaluation and Research), Tracy A. Lieu(Harvard University), Robert L. Davis(Southeast Health District), Aysha Akhtar(Institute of Contemporary History), Jason M. Glanz(Kaiser Permanente), Roger Baxter(Unknown), Matthew F. Daley(Kaiser Permanente)
Cited by 114
Related Papers
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|720
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Management of Neonates Born at ≥35 0/7 Weeks’ Gestation With Suspected or Proven Early-Onset Bacterial Sepsis
|PEDIATRICS|2018|462
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
|PubMed|2003|397
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System
|The Pediatric Infectious Disease Journal|2004|381